Literature DB >> 25296560

Tailored selection of the interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer: analysis based on the pathologic stage or chemoradiation response.

Kai-yun You1, Rong Huang, Lu-ning Zhang, Pei-rong Ding, Wei-wei Xiao, Bo Qiu, Hui Chang, Zhi-fan Zeng, Zhi-zhong Pan, Yuan-hong Gao.   

Abstract

BACKGROUND: The optimal interval between neoadjuvant chemoradiotherapy (CRT) and surgery has yet to be established. Additionally, it is unknown whether patients with different pathologic stages or chemoradiation responses should undergo different intervals between CRT and surgery. Therefore, the purpose of this study was to evaluate whether this interval has a differential effect on the oncologic outcome of patients with different chemoradiation responses or pathologic stages.
METHODS: We performed a retrospective study of 291 rectal cancer patients who were treated with preoperative chemoradiation and surgery between March 2004 and November 2012. All patients were separated into two groups according to a 7-week treatment interval. Overall survival (OS) and disease-free survival (DFS) were compared between patients undergoing intervals that were shorter and longer than 7 weeks in the entire group and in subgroups of ypT0-2N0, ypT3-4N0 and ypT0-4N+. The recurrence patterns were also analysed in all of the subgroups. Multivariate analysis was performed to explore the clinical factors that were significantly associated with DFS, local recurrence-free survival (LRFS) and distant metastasis-free survival among patients exhibiting ypT3-4N0 and ypT0-4N+.
RESULTS: For the ypT0-2N0 patients, the 5-year OS and DFS and the rates of local and distant recurrence were similar between the short and long interval groups. For the patients exhibiting ypT3-4N0, although no significant difference was found in OS or DFS between the short and long interval groups, the rate of local recurrence was higher in the long interval group, which was further confirmed by multivariate analysis. In the patients exhibiting ypT0-4N+, both OS and DFS were lower in the long interval group than in the short interval group. Furthermore, multivariate analysis indicated that the interval was significantly associated with DFS, especially LRFS.
CONCLUSIONS: The interval between CRT and surgery may exert a differential effect on the prognosis of patients exhibiting different pathologic stages or chemoradiation responses. Therefore, we strongly suggest tailoring the interval between CRT and surgery in locally advanced rectal cancer.

Entities:  

Mesh:

Year:  2014        PMID: 25296560     DOI: 10.1007/s00432-014-1843-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

2.  The impact of preoperative chemoradiotherapy on advanced low rectal cancer.

Authors:  Ping-Sheng Kao; Shih-Ching Chang; Ling-Wei Wang; Rheun-Chuan Lee; Wen-Yi Liang; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kai Jiang; Shung-Haur Yang; Huann-Sheng Wang; Jen-Kou Lin
Journal:  J Surg Oncol       Date:  2010-12-01       Impact factor: 3.454

3.  Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.

Authors:  Skandan Shanmugan; Rodrigo Arrangoiz; James R Nitzkorski; Jian Q Yu; Tianyu Li; Harry Cooper; Andre Konski; Jeffrey M Farma; Elin R Sigurdson
Journal:  Ann Surg Oncol       Date:  2012-03-07       Impact factor: 5.344

Review 4.  Irinotecan and radiosensitization in rectal cancer.

Authors:  Henrik Illum
Journal:  Anticancer Drugs       Date:  2011-04       Impact factor: 2.248

5.  Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.

Authors:  Chan Wook Kim; Chang Sik Yu; Song-Soo Yang; Kyung Ho Kim; Yong Sik Yoon; Sang Nam Yoon; Seok-Byung Lim; Jin Cheon Kim
Journal:  Ann Surg Oncol       Date:  2011-05-03       Impact factor: 5.344

6.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.

Authors:  D A M Sloothaak; D E Geijsen; N J van Leersum; C J A Punt; C J Buskens; W A Bemelman; P J Tanis
Journal:  Br J Surg       Date:  2013-03-27       Impact factor: 6.939

Review 8.  Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature.

Authors:  Jake D Foster; Emma L Jones; Stephen Falk; Edwin J Cooper; Nader K Francis
Journal:  Dis Colon Rectum       Date:  2013-07       Impact factor: 4.585

9.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.

Authors:  Fausto Petrelli; Giovanni Sgroi; Enrico Sarti; Sandro Barni
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

10.  Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery.

Authors:  A A F A Veenhof; R H J Kropman; A F Engel; M E Craanen; S Meijer; O W M Meijer; D L van der Peet; M A Cuesta
Journal:  Int J Colorectal Dis       Date:  2006-09-29       Impact factor: 2.796

View more
  5 in total

1.  Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer.

Authors:  Bailey Nelson; Jane V Carter; Maurice R Eichenberger; Uri Netz; Susan Galandiuk
Journal:  Surgery       Date:  2016-07-14       Impact factor: 3.982

2.  Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.

Authors:  Eva Dreussi; Erika Cecchin; Jerry Polesel; Vincenzo Canzonieri; Marco Agostini; Caterina Boso; Claudio Belluco; Angela Buonadonna; Sara Lonardi; Francesca Bergamo; Sara Gagno; Elena De Mattia; Salvatore Pucciarelli; Antonino De Paoli; Giuseppe Toffoli
Journal:  Int J Mol Sci       Date:  2016-09-05       Impact factor: 5.923

3.  Temporal determinants of tumour response to neoadjuvant rectal radiotherapy.

Authors:  Kendrick Koo; Rachel Ward; Ryan L Smith; Jeremy Ruben; Peter W G Carne; Hany Elsaleh
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

Review 4.  Effect of Interval between Neoadjuvant Chemoradiotherapy and Surgery on Oncological Outcome for Rectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Xiao-Jie Wang; Zheng-Rong Zheng; Pan Chi; Hui-Ming Lin; Xing-Rong Lu; Ying Huang
Journal:  Gastroenterol Res Pract       Date:  2016-03-30       Impact factor: 2.260

5.  Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.

Authors:  Eva Dreussi; Salvatore Pucciarelli; Antonino De Paoli; Jerry Polesel; Vincenzo Canzonieri; Marco Agostini; Maria Luisa Friso; Claudio Belluco; Angela Buonadonna; Sara Lonardi; Chiara Zanusso; Elena De Mattia; Giuseppe Toffoli; Erika Cecchin
Journal:  Oncotarget       Date:  2016-04-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.